BI 754132
/ Boehringer Ingelheim
- LARVOL DELTA
Home
Next
Prev
1 to 12
Of
12
Go to page
1
July 01, 2026
Tropomyosin-Related Kinase Receptor Type B Agonism in Geographic Atrophy-The Translational Challenges from Preclinical Data to a First-in-Human Trial.
(PubMed, Ophthalmol Sci)
- P1 | "To report results of the first-in-human trial of intravitreal tropomyosin-related kinase receptor type B (TrkB) agonist BI 754132 in participants with geographic atrophy (GA)...Although the underlying mechanisms remain unclear, these data warrant caution during further exploration of TrkB agonism in GA and highlight the role of monitoring safety data during early clinical development, especially when studying new modes of action. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."
First-in-human • Journal • P1 data • Preclinical • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders
August 24, 2022
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1 | N=18 | Terminated | Sponsor: Boehringer Ingelheim | N=30 ➔ 18 | Suspended ➔ Terminated; The trial was discontinued in the interests of patients considering benefit/risk balance.
Enrollment change • Trial termination • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
July 12, 2022
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1 | N=30 | Suspended | Sponsor: Boehringer Ingelheim | Trial completion date: Nov 2022 ➔ Aug 2022 | Trial primary completion date: Nov 2022 ➔ Aug 2022
Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
April 28, 2022
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1 | N=30 | Suspended | Sponsor: Boehringer Ingelheim | Recruiting ➔ Suspended
Trial suspension • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
November 04, 2021
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=24; Recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Jun 2022 ➔ Nov 2022; Trial primary completion date: Jun 2022 ➔ Nov 2022
Clinical • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
June 02, 2021
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=24; Recruiting; Sponsor: Boehringer Ingelheim; Trial primary completion date: Mar 2022 ➔ Jun 2022
Clinical • Trial primary completion date • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
January 28, 2021
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=24; Recruiting; Sponsor: Boehringer Ingelheim; N=18 ➔ 24
Clinical • Enrollment change • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
July 02, 2020
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Mar 2022 ➔ Jun 2022
Clinical • Trial completion date • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Dry Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders
May 27, 2020
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Boehringer Ingelheim; Suspended ➔ Recruiting; Trial completion date: Apr 2021 ➔ Mar 2022; Trial primary completion date: Apr 2021 ➔ Mar 2022
Clinical • Enrollment open • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Dry Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders
April 07, 2020
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=18; Suspended; Sponsor: Boehringer Ingelheim; Trial completion date: Jan 2021 ➔ Apr 2021; Recruiting ➔ Suspended
Trial completion date • Trial suspension
November 15, 2019
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Jun 2020 ➔ Oct 2020; Trial primary completion date: Jun 2020 ➔ Oct 2020
Clinical • Trial completion date • Trial primary completion date
July 31, 2019
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Boehringer Ingelheim; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
1 to 12
Of
12
Go to page
1